MARKET

VVUS

VVUS

VIVUS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.440
+0.030
+1.24%
Closed 16:00 02/21 EST
OPEN
2.400
PREV CLOSE
2.410
HIGH
2.520
LOW
2.300
VOLUME
222.70K
TURNOVER
--
52 WEEK HIGH
5.25
52 WEEK LOW
2.100
MARKET CAP
25.97M
P/E (TTM)
-0.8813
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VVUS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VVUS stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.

EPS

VVUS News

More
  • Vivus up 4% premarket on Qsymia launch in Korea
  • seekingalpha · 3d ago
  • TSLA, PLUG among premarket gainers
  • Seeking Alpha - Article · 3d ago
  • VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream
  • GlobeNewswire · 3d ago
  • VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020
  • GlobeNewswire · 4d ago

Industry

Pharmaceuticals
+0.60%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About VVUS

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
More

Webull offers kinds of VIVUS, Inc. stock information, including NASDAQ:VVUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VVUS stock news, and many more online research tools to help you make informed decisions.